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Tissue factor (TF), an initiator of the extrinsic blood coagulation cascade, is over-
expressed in different types of cancer. Tissue factor overexpression is also known
as a poor prognostic factor in pancreatic cancer. We recently developed anti-TF
antibody (clone1849)-conjugated epirubicin-incorporating micelles (NC-6300), and
reported that this anti-TF1849-NC-6300 showed enhanced antitumor activity
against TF-high expressed human pancreatic cancer cells, when compared with
NC-6300 alone. However, clone 1849 antibody inhibited TF-associated blood coag-
ulation activity. We studied another anti-TF antibody, clone 1859, which had no
effect on blood coagulation and prepared anti-TF1859-NC-6300. In addition, to
determine the optimum size of the antibody fragment to conjugate with
NC-6300, three forms of the 1859 antibody (whole IgG, F[ab’]2, and Fab’) were
conjugated to NC-6300. The antitumor effect of each anti-TF1859-NC-6300 was
studied in vitro and in vivo, using two human pancreatic cancer cell lines, BxPC3
with high-expressed TF, and SUIT2 with low levels of TF. In vitro, all forms of
anti-TF1859-NC-6300 showed higher cytocidal effects than NC-6300 in BxPC3,
whereas this enhanced effect was not observed in SUIT2. Likewise, all forms of
anti-TF1859-NC-6300 significantly suppressed tumor growth when compared to
NC-6300 in the BxPC3, but not in the SUIT2, xenograft model. Among the three
forms of conjugates, anti-TF1859-IgG-NC-6300 had a higher antitumor tendency
in TF-high expressed cells. Thus, we have confirmed an enhanced antitumor
effect of anti-TF1859-NC-6300 in a TF-high expressing tumor; anti-TF1859-IgG-NC-
6300 could be used to simplify the manufacturing process of the antibody–micelle
conjugation for future clinical studies.
D rug delivery systems using nanoparticles are comprisedof both passive and active targeting. Passive targeting
can be achieved by an EPR effect.(1,2) In active targeting,
mAbs or ligand(s) to tumor-related receptors are conjugated
on the surface of nanoparticles to use the specific binding
ability between an antibody and antigen ⁄ ligand and its
receptor. NC-6300 is an epirubicin-incorporating polymeric
micelle system and exerts an enhanced antitumor effect
through the EPR effect.(3–6) We have recently developed an
antibody-conjugated NC-6300 as a second generation
micelle system; it is a hybrid of active and passive
targeting.
Tissue factor, the trigger protein of extrinsic blood coagula-
tion, is overexpressed in various human tumor cells and is
involved in tumor proliferation, invasion, and metastasis.(7,8) In
addition, overexpression of TF on tumor cells is closely related
to poor patient prognosis in various cancers.(8–13) We previ-
ously developed an anti-TF antibody (clone 1849)(14) conju-
gated with NC-6300 (anti-TF1849-NC-6300) and showed that
it had superior antitumor activity when compared with NC-
6300 alone.(15)
However, we know that the anti-TF1849 antibody inhibits
the blood coagulating activity of TF and may cause a coagula-
tion abnormality in vivo. Therefore, we obtained a new anti-
TF-antibody, clone 1859, which has no anticoagulant activity.
Using this clone, we developed anti-TF1859-NC-6300. In addi-
tion, to determine the optimum size of the antibody fragment
to conjugate with NC-6300, we prepared three different forms
of anti-TF1859-NC-6300: (i) anti-TF1859-IgG-; (ii) anti-
TF1859-F(ab’)2-; and (iii) anti-TF1859-Fab’-NC-6300. We
used the three forms to study antitumor activities of these
micelles in human pancreatic cancer cells.
Materials and Methods
Selection of anti-TF mAb based on the anticoagulant activity
and affinity to human TF antigen. To select a suitable anti-
human TF mAb with less anticoagulant activity and strong
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specific binding affinity, we screened three types of rat anti-
human TF antibodies, which were produced by the hybridoma
clones established previously.(14) To evaluate the anticoagulant
activity of the newly developed mAbs, each mAb (1 nM) and
recombinant human TF (62.5 pM) were reacted for 1 h at
37°C in a 96-well plate. Human coagulation factor VII and X
were then applied to wells and reacted for 30 min at 37°C. At
the termination of the reaction, a substrate specific to activated
human coagulation factor X was applied, and the Xa produc-
tion was estimated by measuring absorbance at 405 nm.
To evaluate the affinities, the antigen–antibody complex reac-
tions of several anti-TF mAbs were assessed by surface plasmon
resonance using Biacore T200 (GE Healthcare, Uppsala, Swe-
den). Recombinant human TF (1 lg ⁄mL) in 10 mM sodium-
acetate was immobilized onto a Series S Sensor chip (CM5) to
yield a binding signal of 20 resonance units, using an amine cou-
pling kit. Various doses of human TF antibody (10-80 nM)
diluted in running buffer (HBS-EP+ buffer; GE Healthcare)
were then injected at a flow rate of 30 lL ⁄min for 1 min of con-
tact time through the sensor chip. The BIA evaluation software
(GE Healthcare) that was obtained using the Langmuir 1:1 bind-
ing model was used to analyze the binding data. The affinity
(KD) was calculated using the equation KD = dissociation rate
constant (Kd) ⁄ association rate constant (Ka).
Test compounds. NC-6300 was prepared by NanoCarrier
Co., Ltd. (Kashiwa, Japan). Epirubicin was purchased from
Pfizer Japan Inc. (Tokyo, Japan).
Preparation of anti-TF1859-NC-6300. Anti-TF1859-IgG (1 mg
⁄mL) was prepared in 10 mM sodium acetate (pH 2.4) and
50 mM (NH4)2SO4. After preheating at 37°C for 15 min, pep-
sin was added at protein : pepsin ratio of 200:1, the reaction
mixture was incubated for 80 min, and the reaction was then
stopped by adding 3 M Tris-HCl (pH 8.5). Gel filtration chro-
matography was carried out using Bio Logic Duo Flow (Bio-
Rad, Hercules, CA, USA), and F(ab’)2 was isolated. Next,
1 mg ⁄mL F(ab’)2 in 5 mM EDTA in PBS was reduced by
adding DTT at a final concentration of 5 mM. The mixture
was then heated at 37°C for 30 min, dialyzed against 5 mM
EDTA in PBS, and the final product, Fab’ of the 1859 anti-
body, was produced. The final products were verified using
SDS-PAGE.
The IgG, F(ab’)2, and Fab’ of the 1859 antibody were conju-
gated with NC-6300 based on our antibody ⁄drug-conjugated
micelle technology described previously(15) (anti-TF1859-IgG-
NC-6300, anti-TF1859-F[ab’]2-NC-6300, and anti-TF1859-
Fab’-NC-6300, respectively). Diameters were measured with a
Zetasizer Nano-ZS (Malvern, Malvern, UK).
Clotting assay. A total of 20 lL human recombinant TF
50 ng, anti-TF1859-IgG 5 lg, or anti-TF1859-(IgG, F[ab’]2 or
Fab’)-NC-6300 (equivalent to 5 lg anti-TF mAb), and ultra-
pure water were incubated at 37°C for 15 min using 96-well
plates; 100 lL citrated normal human plasma and 100 lL
CaCl2 (25 mM) was then added, and the time to fibrin clot for-
mation for each combination was measured. In the control
group, PBS was added. Fibrin precipitation could be quantified
by determining the absorbance at 350 nm, and the time to fib-
rin clot formation was determined when measured absorbance
increased by 25% from baseline. The absorbance was mea-
sured every 45 s at 37°C using a SpectraMax plate reader
(Molecular Devices Japan, Tokyo, Japan). The experiments
were carried out in triplicate.
Cell cultures and cell selection based on tissue factor expres-
sion. The human pancreatic cancer cell lines BxPC3 and
SUIT2 were purchased from ATCC (Rockville, MD, USA)
and from the JCRB Cell Bank (Osaka, Japan) respectively.
Both the cell lines were maintained in RPMI-1640 (Wako,
Osaka, Japan) supplemented with 10% FBS (Gibco, Grand
Island, NY, USA) and 100 units ⁄mL penicillin, and 100 lg
⁄mL streptomycin and 0.25 lg ⁄mL amphotericin B suspension
(Wako) in a 5% CO2 incubator at 37°C.
Cellular uptake and affinity analysis. Flow cytometry was car-
ried out to examine the cellular affinity of antibodies and anti-
TF1859-NC-6300 for BxPC3 and SUIT2. BxPC3 and SUIT2
were washed with PBS and detached by incubation with a
non-enzymatic cell dissociation solution (91) for 15 min at
37°C. Suspensions of cells with B.E. PBS were put into flow
cytometry-compatible tubes (BD Biosciences, Franklin Lakes,
NJ, USA) at 2 9 105 cells ⁄ tube. Suspensions were then cen-
trifuged at 500 g for 5 min, and the supernatant was removed.
The cells were incubated for 30 min on ice with primary anti-
bodies and anti-TF1859-NC-6300 (equivalent to 0.5 lg mAb
for 1 9 106 cells) diluted in B.E. PBS. Then, the cells were
washed with B.E. PBS and incubated for 30 min on ice with
goat anti-rat IgG-Alexa647 (Invitrogen, Grand Island, NY,
USA) as a secondary antibody diluted in B.E. PBS. Controls
contained only secondary antibody without primary antibody.
After washing and staining with propidium iodide, the cells
were applied to a flow cytometer (Guava EasyCyte; GE
Healthcare). Multi-parametric analyses were carried out using
FlowJo 7.5.5 software (Ashland, OR, USA).
In vitro growth inhibition assay. The growth-inhibitory effects
were evaluated by a yellow-color formazan dye produced by
Table 1. Human tissue factor (TF) activity assay of three mAbs
Clone no. Human TF activity, %
1849 5.0  1.8
1006 86.9  0.8
1859 98.5  2.6
Control 100.0  1.8
Table 2. Affinity of three mAbs to human tissue factor antigen
assessed by surface plasmon resonance
Clone no. Ka (1 ⁄ Ms) Kd (1 ⁄ s) KD (M)
1849 4.2.E+05 3.8.E05 9.1.E11
1006 1.5.E+05 1.2.E04 8.3.E10
1859 1.9.E+06 2.4.E04 1.2.E10
The affinity (KD) was calculated using the equation: KD = dissociation
rate constant (Kd) ⁄ association rate constant (Ka).
Table 3. Particle size of NC-6300 and anti-TF1859-IgG-, anti-TF1859-F(ab’)2-, and anti-TF1859-Fab’-NC-6300
NC-6300 Anti-TF1859-IgG-NC-6300 Anti-TF1859-F(ab’)2-NC-6300 Anti-TF1859-Fab’-NC-6300
Mean particle diameter, nm 54.3  0.24 58.3  0.44 54.2  0.76 48.4  0.35
TF, tissue factor.
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dehydrogenase activities in cells of tetrazolium salt (WST-8).
BxPC3 and SUIT2 were plated at 2000 cells in 100 lL med-
ium ⁄well in 96-well plates and were incubated for 24 h at
37°C. The medium was removed, and cells with each com-
pound (epirubicin, NC-6300, anti-TF1859-IgG-NC-6300, anti-
TF1859-F[ab’]2-NC-6300, or anti-TF1859-Fab’-NC6300) with
medium at an epirubicin equivalent of 0.1, 1, 10, and 100 nM
and 1, 10, and 100 lM were then incubated for 96 h. At the
termination of the incubation, the medium was removed, and
100 lL of a 10% WST-8 solution was added to each well and
incubated for 2 h at 37°C. Absorbance value at 450 nm was
measured using the SpectraMax plate reader. As a result of
these measurements, a 50% inhibitory concentration (IC50) was
obtained.
In vivo antitumor activity. Female BALB ⁄ c nu ⁄nu mice were
purchased from Charles River Japan (Yokohama, Japan). They
were maintained under specific pathogen-free conditions in
cages, provided with standard food, and given free access to
sterilized water. Five-week-old mice were s.c. inoculated with
1 9 107 BxPC3 cells or 2 9 106 SUIT2 cells in the flank
region. Seven or 14 days after inoculation with BxPC3 or
SUIT2, respectively, when the tumor size had reached approxi-
mately 180 mm3, the mice were randomly divided into six test
groups consisting of five mice each (day 0). Mice were
injected i.v. with the test compound through the lateral tail
vein on days 0, 7, and 14. The test groups received anti-
TF1859-IgG-NC-6300, anti-TF1859-F(ab’)2-NC-6300, anti-
TF1859-Fab’-NC-6300, NC-6300, or free epirubicin in saline.
The concentration of each compound was 10 mg ⁄kg epirubicin
equivalents. The normal control group received saline. The
length (a) and width (b) of the tumor masses and body weights
were measured biweekly, and the tumor volume (TV) was cal-
culated as follows: TV = (a 9 b2) ⁄2. From an ethical point of
view, animals in which the tumor volume exceeded 2000 mm3
were euthanized. All animal experiments were carried out in
compliance with the Guidelines for the Care and Use of
Experimental Animals approved by the Committee for Animal
Experimentation of the National Cancer Center, Japan.
Statistics. Clotting assay data were reported as mean  SD,
using multiple comparison to a control (Dunnett’s one-sided
test). The IC50 data were reported as mean  SD, using multi-
ple comparison (Tukey’s HSD, two-sided test). In vivo data
was evaluated by post-hoc comparison, which is a repeatedly
measured ANOVA followed by multiple comparison (Tukey’s
HSD, two-sided test). The level of significance for all the tests
was set at P < 0.05. These analyses were carried out using SPSS
version 18.0 (SPSS, Chicago, IL, USA).
Results
Selection of anti-TF mAb based on anticoagulant activity and
affinity to human TF antigen. Compared with controls, the
human TF activity influenced by clones 1849, 1006, and 1859
were 5%, 87%, and 98%, respectively. The data indicated that
anti-TF1859 possessed the lowest anticoagulant activity among
mAbs tested (Table 1).
The affinities of the three clones were evaluated by surface
plasmon resonance sensing. Clones 1849, 1006, and 1859 had
the KD value of approximately 9.1 9 1011 M,
8.2 9 1010 M, and 1.2 9 1010 M, respectively (Table 2).
Clone 1849 had the highest and 1859 had the second highest
affinities. The association constant (Ka) of 1859 was slightly
higher than 1849, whereas its dissociation constant (Kd) was
lower than 1849. Consequently, clone 1859 was selected
because it had the least anticoagulant activity and the second
highest affinity to the human TF antigen.
Characteristics of micelles. The mean particle diameters of
anti-TF1859-IgG-NC-6300, anti-TF1859-F(ab’)2-NC-6300, and
anti-TF1859-Fab’-NC-6300 were 58.3  0.44, 54.2  0.76,
and 48.4  0.35 nm, respectively (Table 3). Those particular
Fig. 1. Time to fibrin clot formation with anti-TF1859 antibody and
anti-TF1859-IgG-NC-6300 was measured using a clotting assay. The
time was determined when the absorbance at 350 nm increased by
25% from baseline. Data are expressed as the mean  SD; n = 4. TF,
tissue factor.
Fig. 2. Comparative binding activities were
determined with flow cytometry analysis among
anti-TF1859-NC-6300 using BxPC3 (tissue factor [TF]-
high expressing) and SUIT2 (TF-low expressing)
pancreatic cancer cells.
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micelle formulations contained the same amount of epirubicin
per micelle, and the numbers of antibodies tagged to micelles
were two to four molecules per micelle in all three formulations.
Clotting assay. The time to fibrin clot formation in the incuba-
tion with anti-TF1859-IgG-NC-6300, anti-TF1859-F(ab’)2-NC-
6300, anti-TF1859-Fab’-NC-6300, and control were 43  1,
44  7, 37  2, and 49  3 min (P = 0.997, P = 0.995, and
P = 1.000, compared to control), respectively (n = 4). The
three forms of anti-TF1859-NC-6300 did not prolong the fibrin
clot formation time when compared with the control (Fig. 1).
Flow cytometry analysis of anti-TF1859-NC-6300. Binding
affinities of three formulations of anti-TF-NC-6300 conjugated
with 1859 IgG, F(ab’)2, and Fab’ were almost the same as that
of anti-TF mAb in BxPC3. The binding activities of the three
formulations of anti-TF1859-NC-6300 and anti-TF1859 mAb
to BxPC3 were approximately 10-fold higher than that to
SUIT2. Otherwise, no significant differences were observed in
terms of the binding activities of IgG, F(ab’)2, and Fab’ to
BxPC3, whereas the affinities of anti-TF (IgG, F[ab’]2, and
Fab’)-NC-6300 and NC-6300 were almost the same in the
SUIT2 cell line (Fig. 2).
In vitro cytotoxicity. The IC50 values of NC-6300, anti-
TF1859-IgG-NC-6300, anti-TF1859-F(ab’)2-NC-6300, and
anti-TF1859-Fab’-NC-6300 for the BxPC3 cells were 329 
23 nM, 224  60 nM, 233  49 nM, and 183  39 nM,
respectively (Table 4). The three forms of anti-TF1859 (IgG, F
[ab’]2, and Fab’)-NC-6300 were all superior to NC-6300 in the
BxPC3 cell line in terms of cell killing effectiveness in vitro
(P = 0.026, 0.043, 0.003, respectively). No significant differ-
ences were observed among the three forms of anti-TF1859-
NC-6300 in the BxPC3 cell line. In contrast, the IC50 values
of NC-6300, anti-TF1859-IgG-NC-6300, anti-TF1859-F(ab’)2-
Table 4. Inhibitory concentration values of various drugs in
pancreatic cancer cell lines using WST-8 assay
Drug
BxPC3 SUIT2
IC50, nM P-value IC50, nM P-value
Epirubicin 65  2 145  40
NC-6300 329  23 636  13
Anti-TF1859-IgG-NC-6300 224  60 0.026* 662  8 0.014*
Anti-TF1859-F(ab’)2-NC-6300 233  49 0.043* 642  3 0.839*
Anti-TF1859-Fab’-NC-6300 183  39 0.003* 634  13 0.996*
Anti-TF1859-IgG N ⁄ A N ⁄ A
*P-value versus NC-6300. N ⁄ A, not applicable; TF, tissue factor.
Fig. 3. In vivo tumor growth inhibition assay. Antitumor activities and changes in body weight in xenograft mice models in BxPC3 (a,b) and
SUIT2 (c,d) pancreatic cancer cell lines. The treatment was given on days 0, 7, and 14 (n = 5). ♦, Control; ■, epirubicin; ▲, NC-6300; 9, anti-
TF1859Fab’-NC-6300; *, anti-TF1859-F(ab’)2-NC-6300; ●, anti-TF1859-IgG-NC-6300. Arrows, compound injections; bars, SD; points, mean.
© 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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NC-6300, and anti-TF1859-NC-6300 for the SUIT2 cells were
636  13 nM, 662  8 nM, 642  3 nM, and 634  13 nM,
respectively (Table 4). The three forms of anti-TF1859 (IgG, F
[ab’]2, and Fab’)-NC-6300 were not superior to NC-6300 in
the SUIT2 cell line (P = 0.014, 0.839, 0.996, respectively).
In vivo tumor growth inhibition assay. The antitumor activi-
ties of anti-TF1859-IgG-NC-6300, anti-TF1859-F(ab’)2-
NC-6300, and anti-TF1859-Fab’-NC-6300 exceeded that of
NC-6300 in the BxPC3 xenograft models (P = 0.021,
P < 0.001, P < 0.001, respectively; Fig. 3a). Among anti-
TF1859-NC-6300, anti-TF1859-IgG-NC-6300 versus anti-
TF1859-F(ab’)2-NC6300 and anti-TF1859-F(ab’)2-NC-6300
versus anti-TF1859-Fab’-NC-6300 were not significant. Anti-
TF1859-IgG-NC-6300 was superior to anti-TF1859-Fab’-NC-
6300 (P = 0.002). In contrast, in SUIT2 xenografts, anti-
TF1859-IgG-NC-6300, anti-TF1859-F(ab’)2-NC-6300, and
anti-TF1859-Fab’-NC-6300 were all equivalent to NC-6300
(Fig. 3c). There were no treatment-related deaths. No signifi-
cant body weight loss was observed among any of the anti-
TF1859-NC-6300 groups, NC-6300 groups, or control groups.
However, the free epirubicin administration groups showed
significant body weight loss compared with all the other
groups in both BxPC3 and SUIT2 models (Fig. 3b,d).
Discussion
In the present study, anti-TF1859-NC-6300 showed superior
antitumor activity to NC-6300 in the TF-high expressing
human pancreatic cancer model. This is similar to our previous
report concerning anti-TF1849-NC-6300.(15) Anti-TF1849-NC-
6300 was distributed throughout all of the tumor tissues and
was efficiently internalized into tumor cells; it showed potent
antitumor activity in TF-high expressing cancer cells, indicat-
ing that the conjugation of anti-TF mAb to micelles offered
that advantage. The present study showed that no differences
in tumor growth inhibition among three forms of anti-TF1859-
NC-6300 and NC-6300 were observed in the xenograft SUIT2.
The sizes of the three forms of anti-TF1859-NC-6300 ranged
from 50 to 60 nm, which was not very different from the
50 nm size of non-modified NC-6300. This result indicates
that the slightly larger size of anti-TF1859-NC-6300 did not
affect the EPR effects within these size ranges. In the TF-high
expressing BxPC3 xenograft, anti-TF1859-IgG-NC-6300
tended to have a superior effect when compared to the Fab’
fragment forms, although there were no significant differences
among the three types of the antibody–micelle conjugates. To
simplify the manufacturing process of the mAb–micelle conju-
gation, it is reasonable to select the whole IgG of 1859 mAb
for further studies. In addition, as previously reported,(15) we
showed that a higher tumor accumulation of anti-TF-NC-6300
compared to NC-6300 was seen, regardless of the TF expres-
sion levels. In order to examine the immunological and phar-
macokinetic effects by the formulation of various
immunoconjugates, we will have to analyze pharmacokinetic
parameters of total epirubicin (micelle-encapsulated epirubicin
and free epirubicin) and free epirubicin in plasma for future
clinical pharmacology. Although we are developing a chimeric
human mAb of the clone used in this study, difference in anti-
genicity of antibodies (IgG, F(ab’)2, and Fab’) on micelles
should also be evaluated before the clinical trial using a non
human primate model.
As a possible adverse effect of anti-TF1849-NC-6300, a ten-
dency towards bleeding is of concern, as anti-TF1849 has anti-
coagulant activity. However, we are not sure whether it
actually causes a bleeding tendency in clinical use. Our present
data indicated that anti-TF1859 mAb and its conjugated
micelles may not cause a bleeding tendency in humans
because they have no anticoagulant activity in human blood.
Unfortunately, both anti-human TF antibodies, clones 1849
and 1859, used in this study, have no cross-reactivity with
mouse TF; thus, we could not assess their influence on mouse
blood coagulation in vivo. Therefore, this issue should be eval-
uated in clinical studies.
In contrast with results in oncology patients, hematuria was
observed in 44% patients who were treated with anti-TF
antibody for acute respiratory distress syndrome in a phase 1
clinical trial.(16) With regard to solid tumors, anticancer drugs
conjugated with human TF antibody were developed in pre-
clinical studies.(17,18) Safety and toxicity concerns are currently
under evaluation in the first in-human clinical trial.(17)
In conclusion, anti-TF1859-NC-6300 has a low risk of
bleeding because of its low anticoagulant activity, and it has a
potent antitumor effect in a human pancreatic cancer model,
especially TF-high expressing tumors. Results from the present
study warrant a comparative clinical evaluation of efficacy and
safety between anti-TF1859-IgG-NC-6300 and anti-TF1849-
IgG-NC-6300.
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